Rosetta Genomics Surges, Shares Rise 1000% in 8 Trading Days

Shares of Rosetta Genomics

are currently trading off the highs, though still up 70% on for the day. Shares rose as high as 23.34 on Thursday, up from around $2.00 on May 15, following a 1:15 reverse split. On May 16, the Israel-based molecular diagnostics company, announced that Novitas, the designated Medicare Administrative Contractor for the Company's miRview mets² assay, informed Rosetta that it plans to cover this assay for all Medicare beneficiaries. MiRview mets² accurately identifies the primary tumor of origin in primary and metastatic cancer including Cancer of Unknown or Uncertain Primary. Other related stocks moving in sympathy with Rosetta Genomics on Thursday include Complete Genomics

, up 35%, Vermillion

, up 25% and Genetic Technologies

, up 56%.